Abstract 1234P
Background
Recently, the field of digital pathology has seen an increase in research utilizing deep learning techniques. This allows for predictions such as cancer diagnosis, prognosis, and treatment response, which previously required additional analysis, such as genetic analysis that was both time-consuming and costly, to be made based on pathological imaging. However, digital pathology images often contain noise, such as inconsistent staining and inconsistent annotations. To address this issue, image preprocessing is essential in deep learning analysis of digital pathology images, and various preprocessing techniques have been proposed to address issues such as bias, overfitting, and robust deep learning model development. However, automated preprocessing methods for digital pathology images have not yet been fully developed.
Methods
To address this, we have developed a user-friendly tool for image preprocessing analysis called HistoMate.
Results
HistoMate provides GUI-based image segmentation, image tiling, color normalization, and deep learning-based data augmentation to automate the preprocessing process. It also provides functionality to evaluate image quality and select appropriate patches.
Conclusions
In conclusion, HistoMate provides an automated preprocessing tool for pathological image-based research, accelerating digital pathology-based research.
Clinical trial identification
Editorial acknowledgement
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT) (grant no. NRF-2021R1C1C1013706), and research fund by Seoul National University Bundang Hospital (grant no. 14-2018-0013).
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT) (grant no. NRF-2021R1C1C1013706), and research fund by Seoul National University Bundang Hospital (grant no. 14-2018-0013).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1794P - Prognostic role of metastatic site in patients with de novo metastatic prostate cancer: A population-based analysis in new hormonal agents era
Presenter: Emre Yekeduz
Session: Poster session 14
1795P - China ARCHES: A multicenter phase III randomized double-blind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) + androgen deprivation therapy (ADT) vs PBO + ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Gongqian Zeng
Session: Poster session 14
1796P - Real-world analysis of metastatic hormone-sensitive prostate cancer: Are randomized clinical trials more trustworthy? Insights from PIONEER, the European network of excellence for big data in prostate cancer
Presenter: Juan Gómez Rivas
Session: Poster session 14
1797P - Application of novel machine learning model in [68Ga] Ga-PSMA-11 PET/CT: Predicting survival in oligometastatic prostate cancer patients
Presenter: Mikaela Dell'Oro
Session: Poster session 14
1800P - Differential tumor gene-expression profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (dn-mCSPC) versus (vs.) mCSPC relapsing after prior localized therapy (PLT-mCSPC)
Presenter: Vinay Mathew Thomas
Session: Poster session 14
1803P - Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with <italic>AR</italic> ligand-binding domain (LBD) mutations
Presenter: Daniel Petrylak
Session: Poster session 14